These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34592956)

  • 1. Manifestation of Susac syndrome during interferon beta-1a and glatiramer acetate treatment for misdiagnosed multiple sclerosis: a case report.
    Roskal-Wałek J; Biskup M; Dolecka-Ślusarczyk M; Rosołowska A; Jaroszyński A; Odrobina D
    BMC Ophthalmol; 2021 Sep; 21(1):352. PubMed ID: 34592956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susac syndrome misdiagnosed as multiple sclerosis with exacerbation by interferon beta therapy.
    Algahtani H; Shirah B; Amin M; Altarazi E; Almarzouki H
    Neuroradiol J; 2018 Apr; 31(2):207-212. PubMed ID: 28644112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exacerbation of Susac syndrome retinopathy by interferon Beta-1a.
    Laird PW; Newman NJ; Yeh S
    Arch Ophthalmol; 2012 Jun; 130(6):804-6. PubMed ID: 22801853
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis.
    Lana-Peixoto MA; Teixeira AL; Haase VG
    Arq Neuropsiquiatr; 2002 Sep; 60(3-B):721-4. PubMed ID: 12364937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors leading patients to discontinue multiple sclerosis therapies.
    Daugherty KK; Butler JS; Mattingly M; Ryan M
    J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
    Dhib-Jalbut S
    Neurology; 2002 Apr; 58(8 Suppl 4):S3-9. PubMed ID: 11971121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.
    Pöllmann W; Erasmus LP; Feneberg W; Then Bergh F; Straube A
    Neurology; 2002 Aug; 59(4):636-9. PubMed ID: 12196668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a.
    Schott E; Paul F; Wuerfel JT; Zipp F; Rudolph B; Wiedenmann B; Baumgart DC
    World J Gastroenterol; 2007 Jul; 13(26):3638-40. PubMed ID: 17659718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.
    Wong J; Gomes T; Mamdani M; Manno M; O'Connor PW
    Can J Neurol Sci; 2011 May; 38(3):429-33. PubMed ID: 21515501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups.
    Pavelek Z; Novotny M; Soucek O; Krejsek J; Sobisek L; Sejkorova I; Masopust J; Kuca K; Valis M; Klimova B; Stourac P
    Mult Scler Relat Disord; 2021 Aug; 53():103082. PubMed ID: 34166982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis and glatiramer acetate: Risk factors for central retinal vein occlusion?
    Pascual-Santiago MA; Burgos-Blasco BP; Enríquez-Fuentes JE; Fernandez-Vigo JI
    J Fr Ophtalmol; 2023 Mar; 46(3):235-238. PubMed ID: 36774312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of dimethyl fumarate as first line therapy in MS patients - one center real life observation study.
    Sałacińska D; Pogoda A; Żółkiewicz J; Stępień A
    Pol Merkur Lekarski; 2019 Dec; 47(282):221-225. PubMed ID: 31945023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.
    Galetta SL; Markowitz C; Lee AG
    Arch Intern Med; 2002 Oct; 162(19):2161-9. PubMed ID: 12390057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features, diagnostic findings, and treatment of Susac syndrome: a case series.
    Vodopivec I; Venna N; Rizzo JF; Prasad S
    J Neurol Sci; 2015 Oct; 357(1-2):50-7. PubMed ID: 26148931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.